Respiratory Syncytial Virus in Older Adults: Understanding Risk, Diagnosis, and Evolving Prevention Strategies

Learn about risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccine strategies for older adults.
Spencer Durham Headshot
Spencer H. Durham, PharmD, BCPS, BCIDP
person default
Stefan Gravenstein, MD, MPH
person default
Barbara Resnick, PhD, CRNP
Format: Microsoft PowerPoint (.ppt)
File Size: 553 KB
Released: June 25, 2021

Acknowledgements

This activity is provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Janssen Therapeutics, Division of Janssen Products, LP

Related Content

From Clinical Care Options (CCO), a patient’s perspective on the road to diagnosis and life with nontuberculous mycobacterial (NTM) lung disease

person default Anonymous Patient Released: September 30, 2021

From Elliott Bosco, PharmD, and Clinical Care Options (CCO), expert commentary on the risks and costs of RSV to older adults in the United States

person default Elliott Bosco, PharmD, PhD Released: August 11, 2021

Video from CCO: overview of respiratory syncytial virus illness and vaccine development in older adults from Drs. Spencer Durham, Stefan Gravenstein, and Barbara Resnick.

Spencer Durham Headshot Spencer H. Durham, PharmD, BCPS, BCIDP person default Stefan Gravenstein, MD, MPH person default Barbara Resnick, PhD, CRNP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: July 21, 2021 Expired: July 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue